Premium
Temporal Analysis of Coagulopathy in Burn Sepsis using a Systems Biology Approach
Author(s) -
Srinivasan Seshamalini,
Donohue Duncan,
Gautam Aarti,
Detwiler Leanne,
McLawhorn Melissa M.,
Tejiram Shawn,
Moffatt Lauren T.,
Jett Marti,
Shupp Jeffrey W.,
Hammamieh Rasha
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.927.2
Subject(s) - coagulopathy , sepsis , medicine , systemic inflammatory response syndrome , intensive care medicine , septic shock , population , bioinformatics , biology , environmental health
Coagulopathy is described in the trauma patient population, but to date is studied less in burn patients. The pattern of changes in coagulation that have been described in burn patients are unclear, yet the changes resemble those found in patients with sepsis. The aim of this study was to use a systems biology approach to integrate multiple data types, including clinical findings and transcriptomics, to develop a universal picture of the progression of these physiological conditions. As part of a larger study, seventeen adult burn patients were selected and deemed ‘septic’ based on a positive blood culture and having two or more of the SIRS (systemic inflammatory response syndrome) criteria as abstracted from charts. Blood samples were collected every 2–4 h for the first 12 h, then every 12 h up to day 7, and on a weekly basis until 21 days post admission for a total of 20 samples. Comprehensive demographics, injury, treatment and outcome data were collected and tested for association with coagulopathy at baseline and continually throughout the study. This clinical data was integrated with time series analysis of gene transcript microarray data, which probes over 50,000 biological features, completed on all samples. Further characterization of coagulopathy seen in burn patients with sepsis may add important information to identify biomarkers of disease progression and associate these with appropriate therapeutic strategies as the illness proceeds. DISCLAIMER: The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as official Department of the Army position, policy, or decision, unless so designated by other official documentation.